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Acute viral bronchiolitis is associated with lower 
respiratory tract infections in infants. Although 
generally self-limiting and managed in the community, 
acute viral bronchiolitis is the most common cause of 
hospital admission in infants younger than 12 months 
of age, and is associated with substantial morbidity 
and health-care costs. Admissions of infants to hospital 
for bronchiolitis have increased in the past 20 years for 
reasons that might be multifactorial, although the use 
of pulse oximeters and insuﬃ  cient evidence and clarity 
about levels of tolerable hypoxaemia are thought to be 
associated with increased admission rates.1 Additionally, 
duration of hospital stay seems to be determined by the 
requirement for oxygen supplementation, even when 
feeding problems have resolved.2 National guidelines 
in the USA3 and UK4 diﬀ er in their recommendations for 
supplemental oxygen to target acceptable saturations 
(SpO₂) of 90% or higher, or 94% or higher, respectively. 
An observational study in bronchiolitis5 previously 
suggested that length of stay could be reduced 
when lower oxygen cutoﬀ s were chosen, setting the 
stage for the randomised BIDS trial now reported 
by Steve Cunningham and colleagues in The Lancet,6 
which provides welcome evidence about the use of 
supplemental oxygen and oxygen saturation targets in 
bronchiolitis.
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capacity for emergency response among local health 
providers and populations.14 Finally, academics among 
the diaspora should work to quantify the important work 
that diaspora health workers are doing to gain further 
legitimacy as a force for good in global health. Whereas 
a plethora of scholarly work has focused on migration 
by health workers,1–4 there is a dearth of high-quality 
research that investigates the contributions of diaspora 
health workers in health system strengthening in LMICs.
There is an urgent need for all stakeholders—
governments in LMICs and high-income countries, 
non-proﬁ t organisations, academic institutions, and 
development agencies—to create a blueprint that lays 
down clear strategies for the organisation, preparation, 
and engagement of diaspora health workers in health 
system strengthening and emergency preparedness. 
Diaspora health workers deserve an integrated platform 
and organised opportunities to develop meaningful, 
long-term, and sustainable engagements that improve 
health in LMICs, during times of crisis and beyond.
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BIDS reports ﬁ ndings from a multicentre randomised 
equivalence trial of 615 infants aged between 6 weeks 
and 12 months, who presented to eight paediatric 
hospitals in the UK with bronchiolitis. These infants were 
randomly assigned to be monitored either by standard 
oximeters (n=308), or by modiﬁ ed oximeters (n=307) 
which had a skewed algorithm that displayed an SpO₂ 
reading of 94% when the measured value was 90% 
(with adjusted values for SpO₂ 85–100%). Supplemental 
oxygen was given to all infants with an SpO₂ reading 
lower than 94% on their assigned oximeter.
The median time of resolution of cough (the 
primary outcome) was 15 days for both groups 
(95% CI for diﬀ erence –1 to 2), which was within the 
limits of equivalence. As expected, compared with the 
standard group, fewer infants in the modiﬁ ed oximeter 
group needed supplemental oxygen (169 [56%] vs 
223 [73%]), and, when required, supplementation was for 
a signiﬁ cantly shorter duration (5·7 h vs 27·6 h) and the 
infants were ﬁ t for discharge signiﬁ cantly earlier (30·2 h vs 
44·2 h). More unexpectedly, infants in the modiﬁ ed group 
returned to adequate feeding a median of 2·7 h sooner, 
were perceived to return to normal by their parents 
1 day earlier, and had fewer readmissions to hospital 
within 28 days compared with those in the standard 
group. Adverse events did not diﬀ er between groups. The 
authors conclude that children with bronchiolitis could 
be managed with an oxygen saturation target of 90% 
or higher, instead of 94% or higher, with no short-term 
safety implications. This would result in earlier discharge 
home from hospital with the potential for health-care-
cost reduction and improved quality of life for parents.
The primary outcome chosen by Cunningham and 
colleagues6 (resolution of cough) was unusual for clinical 
trials of bronchiolitis, although duration of cough is 
perceived to be important by families.7 The association 
between duration of cough and degree of hypoxaemia 
is not established, and it is interesting to speculate 
whether the results of cough duration would have 
been any diﬀ erent if an even lower saturation cutoﬀ  
was chosen. Cunningham and colleagues suggest a 
potential interaction with airway inﬂ ammation, and it is 
also possible that cough might become more frequent 
with worsening hypoxia given the association between 
cough frequency and altitude8 and the as yet unexplained 
association between nocturnal cough and obstructive 
sleep apnoea reported in adults.9 Of the other outcomes 
measured, the time to suﬃ  cient feeding and frequency 
of apnoea were possibly more discerning outcomes 
that could have been aﬀ ected by hypoxia. The parental 
perception of return to normalcy might be biased by early 
discharge home, but, like readmission to hospital, would 
also reﬂ ect the parental level of concern about the infant.
Although Cunningham and colleagues’ study6 
provides convincing evidence that reduced oxygen 
saturation targets in bronchiolitis are safe in the short 
term, unfortunately the longer-term neurocognitive 
and behavioural outcomes are unknown. On one hand, 
the likely safety of the lower oxygen saturation target is 
supported from a physiological perspective because the 
oxygen–haemoglobin dissociation curve predicts that the 
actual oxygen delivered to tissues is unlikely to be very 
diﬀ erent with an oxygen saturation target of 90% instead 
of 94%, although risk factors such as fever and acidosis 
need to be taken into account. In addition, intermittent 
desaturation episodes of short duration (up to 6 s) have 
no adverse consequences in infancy.10
On the other hand, intermittent hypoxia over a 
prolonged period of months to years, as in sleep 
disordered breathing and long-term hypoxaemia due to 
altitude or congenital heart disease, has been associated 
with detrimental eﬀ ects on long-term neurocognitive 
outcomes in children.11 The resulting quandary is in 
clinical situations such as bronchiolitis or asthma, which 
lie somewhere between these two ends of the spectrum 
in terms of duration of lower saturations, when the 
longer-term safety of lower saturation targets falls into 
an evidence-free zone. When the American Academy 
of Pediatrics bronchiolitis guidelines3 were published in 
2007 suggesting 90% as the acceptable saturation cutoﬀ , 
Bass and Gozal12 raised concerns about the potential 
detrimental eﬀ ects on cognitive and behavioural 
outcomes, and concerns among paediatricians continue 
to be raised.13
Findings from BIDS6 also raise questions about the use 
of supplemental oxygen in other acute hypoxic states, 
such as exacerbations of asthma and community-
acquired pneumonia. The decision about acceptable 
oxygen saturations for these disorders is also based 
on expert opinion and becomes a matter of clinical 
judgment, availability of health-care resources, and cost 
implications. Cunningham and colleagues have done a 
commendable job in bringing robust evidence with far-
reaching implications to an area previously governed 
BS
IP
/U
IG
Comment
1018 www.thelancet.com   Vol 386   September 12, 2015
Multimodal treatment of non-small-cell lung cancer 
In The Lancet, Miklos Pless and colleagues1 report a 
prospective randomised trial of induction chemotherapy 
followed by accelerated radiotherapy and surgery, 
compared with induction chemotherapy followed 
by surgery, to treat patients with stage IIIA/N2 non-
small-cell lung cancer. 232 patients were enrolled in 
23 study centres and were randomly assigned to the 
study groups in a 1:1 ratio. Median event-free survival, 
the trial’s primary endpoint, was similar in the two groups 
(12·8 months, 95% CI 9·7–22·9 in the chemoradiotherapy 
group and 11·6 months, 8·4–15·2 in the chemotherapy 
group), as was overall survival (37·1 months [22·6–50·0] 
and 26·2 months, 19·9–52·1, respectively). In the 
chemoradiotherapy group around 10% more patients 
had complete R0 resections (90 [91%] vs 76 [81%]). 
The investigators conclude that trimodal therapy might 
not be needed in this subgroup of patients, and that a 
combination of induction chemotherapy and deﬁ nitive 
surgery would be suﬃ  cient. Is this conclusion correct?
The number of patients in Pless and colleagues’ 
trial1 was insuﬃ  cient to show non-inferiority between 
the two strategies and potentially to rule out a 5% 
diﬀ erence in 5-year survival, which is generally induced 
by diﬀ erences in clinical response, pathological 
complete response, and R0 resection rates in larger 
populations. The trial was powered to detect a 
median increase in event-free survival by 6 months 
with radiotherapy, corresponding to a hazard ratio 
of 0·67. The likelihood of stopping a trial for futility 
falls tremendously with a decrease in the assumed 
treatment eﬀ ect as the alternative hypothesis. The 
assumption of a hazard ratio of 0·8, therefore, would 
have been more realistic. Unfortunately, the number of 
patients with stage III non-small-cell lung cancer who 
are treated in prospective randomised trials is currently 
much too small to give clearer recommendations and 
to deﬁ ne the optimum treatment approach with much 
more precision.2–5
The authors used sequential chemotherapy followed 
by accelerated radiotherapy instead of concurrent 
chemoradiotherapy, and noted a rather small diﬀ erence 
in the pathological complete response, from 12% in the 
chemotherapy group to 16% in the chemoradiotherapy 
group. Trials on intensive neoadjuvant concurrent 
chemoradiotherapy have found rates of about 30%.6–8 
In view of the favourable overall survival of patients 
by expert opinion; however, we urge consideration of 
long-term neurobehavioural follow-up of randomised 
trials such as BIDS, to shed light on the nagging 
question that remains.
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